PEG-IFNα/RBV Combination Therapy for Chronic Hepatitis C Patients Increases Serum Ferritin Level while It Improves Sustained Viral Response Rate
Norihisa Yada(Kindai University), Kazuomi Ueshima(Kindai University), Satoru Hagiwara(Kindai University Hospital), Hobyung Chung(Kindai University), Masahiro Takita(Kindai University), Masatoshi Kudo(Kindai University), Satoshi Kitai(Kindai University), Kinuyo Hatanaka(Union Hospital), Tatsuo Inoue, Emi Ishikawa(Kyowa Chemical Industry (Japan)), Sosuke Hayaishi(Union Hospital), Taisuke Ueda(Kindai University), Chie Tatsumi(Kindai University)
Cited by 6
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k